IMUNON, Inc. announced on December 10, 2024, additional clinical data from ongoing analyses of its Phase 2 OVATION 2 Study of IMNN-001. Based on an additional seven months of patient monitoring, the hazard ratio (HR) for overall survival (OS) decreased from 0.74 to 0.69.
The median OS increased from 11.1 to 13 months following treatment with IMNN-001 plus standard-of-care neoadjuvant and adjuvant chemotherapy (NACT) versus NACT alone. More than one-third of patients in the trial survived over 36 months, with 62% of those from the IMNN-001 treatment arm.
Over 10% of trial participants reached 48 months or beyond, and IMNN-001 maintained its favorable safety profile with no serious immune-related adverse events. IMUNON remains on track to initiate the Phase 3 pivotal trial of IMNN-001 in the first quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.